Unfortunately the FDA would not approve a trial with such a wide scope. Cytodyn will have to slog it out with every indication. If a very large pool of patients (10,000, maybe 20,000) start taking leronlimab then a retrospective study could be done (maybe by the NIH). Being a retrospective study the FDA will not accept this as any sort of scientific proof but it will validate the benefits of leronlimab to a wider audience.

Then the Feds can start worrying about bumping up the Social Security retirement age because people will be living longer. But those costs will be offset somewhat by lower payout for Medicare.

Back in 2019 I mentioned leronlimab as a drug that could be used as a regular drug of benefit for those over age 50.